Steven Janvier

janvier.jpgDrug Quality and Registration (DruQuaR) group
Ottergemsesteenweg 460, 9000 Ghent (Belgium)




Ph.D. research





Due to recent advances in peptide synthesis and recombinant expression technologies an increasing number of biopharmaceuticals are being developed and brought on to the market worldwide. Unfortunately, mainly due to the extension of the Internet, counterfeit and illegal marktes for biopharmaceuticals are becoming a growing problem worldwide. Counterfeit of illegal products are usually manufactured without respect to the standard GMP qulity norms and without the necessary quality assurance systems. It stands to reason that counterfeit and illegal biopharmaceuticals can cause severe health related risks due to the absence of the active ingedrient, modifications of the active ingredient, wrong dosages, the wrong ingedrients, the presence of non-approved ingredients that are still under clinical investigation or the presence of toxic impurities.

The focus of this project lies on the development of strategies, techniques and methods for the detection and identification of chemical and/or biological impurities potentially present in those preparations. Furthermore als the functionality and/or toxicity of these illicit biopharmaceuticals will be assessed, to get a better understanding of the potential health risk associated with the usage of these products.

This porject is a collaboration between the Belgian Scientific Institue of Public Health (WIV-ISP), the Federal Agency for Medicines and Health Products (FAMHP) and the Laboratory for Drug Quality & Registration of the UGhent. The knowledge gathered from this project will support national authorities like the FAMHP in their policy and sensitization campaigns.